A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection

AIDS Research and Therapy

Volumn 5, Issue , 2008, Pages

  Ananworanich, Jintanat ^a,b   Kosalaraksa, Pope ^c   Siangphoe, Umaporn ^a,b   Engchanil, Chulapan ^c   Pancharoen, Chitsanu ^d   Lumbiganon, Pagakrong ^c   Intasan, Jintana ^a   Apateerapong, Wichitra ^a,b   Chuenyam, Theshinee ^a   Ubolyam, Sasiwimol ^a   Bunupuradah, Torsak ^a   Lange, Joep ^a,e   Cooper, David A ^a,f   Phanuphak, Praphan ^a  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b The South East Asia Research Collaboration with Hawaii ^*  (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e International Antiviral Therapy Evaluation Centre (IATEC)   (Netherlands)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIBODY; EFAVIRENZ; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBODY BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFERRED ANTIRETROVIRAL THERAPY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMEDIATE ANTIRETROVIRAL THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THAILAND; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; VIRUS LOAD;

EID: 56449098490     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-5-24     Document Type: Article

References (24)

1. Violari A Cotton M Gibb D Babiker A Steyn J Jean-Phillip P McIntyre J Team obotCS: Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study [Abstract WESS 103] 4th IAS Conference on HIV Pathogenesis and Treatment; Sydney, July 22-25, 2007
2. McConnell MS Byers RH Frederick T Peters VB Dominguez KL Sukalac T Greenberg AE Hsu HW Rakusan TA Ortiz IR Melville SK Fowler MG: Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr 2005, 38(4):488-494. 10.1097/ 01.qai.0000134744.72079.cc 15764966
3. Doerholt K Duong T Tookey P Butler K Lyall H Sharland M Novelli V Riordan A Dunn D Walker AS Gibb DM: Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J 2006, 25(5):420-426. 10.1097/01.inf.0000214994.44346.d3 16645506
4. LePrevost M Green H Flynn J Head S Clapson M Lyall H Novelli V Farrelly L Walker AS Burger DM Gibb DM: Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J 2006, 25(6):533-537. 10.1097/ 01.inf.0000222415.40563.d4 16732152
5. McComsey GA Leonard E: Metabolic complications of HIV therapy in children. Aids 2004, 18(13):1753-1768. 10.1097/00002030-200409030-00004 15316336
6. Resino S Resino R Leon JA Bellon JM Martin-Fontelos P Ramos JT Gurbindo-Gutierrez D de Jose MI Ciria L Munoz-Fernandez MA: Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy. BMC Infect Dis 2006, 6:10. 1403782 16433913 10.1186/1471-2334-6-10
7. Dunn D: Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003, 362(9396):1605-1611. 10.1016/ S0140-6736(03)14793-9 14630440
8. Mofenson LM Korelitz J Meyer WA 3rd Bethel J Rich K Pahwa S Moye J Jr Nugent R Read J: The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997, 175(5):1029-1038. 9129063
9. Palumbo PE Raskino C Fiscus S Pahwa S Fowler MG Spector SA Englund JA Baker CJ: Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. Jama 1998, 279(10):756-761. 10.1001/jama.279.10.756 9508151
10. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings, towards universal access: Recommendations for a public health approach http://www.who.int/hiv/mediacentre/ fs_2006guidelinese_praediatric/en/index.html
11. Ministry of Public Health. Thailand National guidelines for the clinical management of HIV infection in children and adult. Bangkok 2007
12. WHO Antiretroviral Therapy for Infants and Children http://www.who.int/ hiv/pub/paediatric/WHO_Paediatric_ART_guideline_rev_mreport_2008.pdf
13. Guidelines for the use of antiretroviral agents in pediatric HIV infection http://www.aidsinfo.nih.gov
14. Sharland M Blanche S Castelli G Ramos J Gibb DM: PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004, 2:61-86. 10.1111/ j.1468-1293.2004.00227.x
15. Mofenson LM Lambert JS Stiehm ER Bethel J Meyer WA 3rd Whitehouse J Moye J Jr Reichelderfer P Harris DR Fowler MG Mathieson BJ Nemo GJ: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999, 341(6):385-393. 10.1056/ NEJM199908053410601 10432323
16. Chearskul S Chotpitayasunondh T Simonds RJ Wanprapar N Waranawat N Punpanich W Chokephaibulkit K Mock PA Neeyapun K Jetsawang B Teeraratkul A Supapol W Mastro TD Shaffer N: Survival, disease manifestations, and early predictors of disease progression among children with perinatal human immunodeficiency virus infection in Thailand. Pediatrics 2002, 110(2 Pt 1):e25. 10.1542/peds.110.2.e25 12165624
17. Vanprapar N Chearsakul S Chokephaibulkit K Phongsamart W Lolekha R: High CD4+ T-cells percentage and/or low viral load are predictors of 1-5 years survival in HIV-1 vertically infected Thai children. J Med Assoc Thai 2002, 85(Suppl 2):S690-693. 12403248
18. Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child 2001, 84(3):230-236. 1718689 11207172 10.1136/adc.84.3.230
19. Darbyshire J Foulkes M Peto R Duncan W Babiker A Collins R Hughes M Peto T Walker A: Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults. Cochrane Database Syst Rev 2000. 3 CD002039
20. Volberding PA Lagakos SW Grimes JM Stein DS Rooney J Meng TC Fischl MA Collier AC Phair JP Hirsch MS: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med 1995, 333(7):401-407. 10.1056/NEJM199508173330701 7616988
21. Concorde Coordinating Committee Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343(8902):871-881. 10.1016/ S0140-6736(94)90006-X 7908356
22. Walker AS Doerholt K Sharland M Gibb DM: Response to highly active antiretroviral therapy varies with age: The UK and Ireland Collaborative HIV Paediatric Study. Aids 2004, 18(14):1915-1924. 10.1097/ 00002030-200409240-00007 15353977
23. Brogly S Williams P Seage GR 3rd Oleske JM van Dyke R McIntosh K: Antiretroviral treatment in pediatric HIV infection in the United States: From clinical trials to clinical practice. Jama 2005, 293(18):2213-2220. 10.1001/jama.293.18.2213 15886376
24. van Leth F Andrews S Grinsztejn B Wilkins E Lazanas MK Lange JM Montaner J: The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. Aids 2005, 19(5):463-471. 10.1097/01.aids.0000162334.12815.5b 15764851